ProdIgY Biotech

ProdIgY Biotech is developing first-in-class, orally administered IgY antibody therapies that target the gut-liver axis to treat serious liver diseases, starting with alcohol-associated hepatitis (AH). Its lead candidate, PRO-AH-001, is designed to selectively neutralize the bacterial toxin cytolysin and its producer, addressing a root cause of disease progression with a non-systemic mechanism. Founded in 2018 and based in San Diego, the company is privately held and pre-revenue, with a preclinical pipeline that also includes programs for Primary Sclerosing Cholangitis (PSC) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The technology is supported by peer-reviewed research, including a 2023 cover publication in Hepatology.

Proprietary platform for developing oral IgY (Immunoglobulin Y) antibody therapeutics derived from avian sources. The platform generates polyclonal antibodies that selectively neutralize specific bacterial toxins and pathogens in the gut to modulate the microbiome and treat liver diseases via the gut-liver axis.

Competition includes other companies developing microbiome-based therapies (e.g., probiotics, prebiotics, fecal microbiota transplantation) and targeted antimicrobials (e.g., bacteriophage therapies) for liver disease. In AH specifically, several biopharma firms are investigating anti-inflammatory, anti-fibrotic, and liver-protective agents, though ProdIgY's toxin-targeting approach is highly differentiated.